- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Coherus Announces Strong Early Sales for Pegfilgrastim Biosimilar, Udenyca
In its announcement, the drug maker said that its Udenyca sales are expected to be in the range of $36 million to $38 million.
Coherus BioSciences, maker of the pegfilgrastim biosimilar Udenyca, has announced its preliminary unaudited sales for the first quarter of 2019. In its announcement, the drug maker said that its Udenyca sales are expected to be in the range of $36 million to $38 million.
The company says that it will discuss its sales in further detail after the data are reported in its Form 10-Q for the quarter, and it will provide additional financial updates on May 9, 2019.
The biosimilar developer brought its pegfilgrastim biosimilar to the US market on January 3, 2019, with a comprehensive launch that included 340B hospitals and non-340B hospitals and clinics. The company launched the product at a list price of $4175 per unit, or a 33% discount to the reference pegfilgrastim, Neulasta. Udenyca’s list price matches that of Mylan’s Fulphila, the first pegfilgrastim biosimilar to launch in the United States, although these list prices do not reflect any rebates that may be provided by the respective drug makers.
The early sales numbers for the biosimilar pegfilgrastim reflect the success of what Coherus’ president and chief executive officer, Dennis M. Lanfear, has called the company’s “branded approach” to the product’s launch.
During the recent 37th Annual J.P. Morgan Healthcare Conference, Lanfear said that “Our approach is that of a branded launch…this has never been done before with a biosimilar.” This strategy involves a focus on payers, integrated delivery networks, and group purchasing organizations that consolidate purchasing for clinics and hospitals, as well as provider segments comprising community oncology clinics, 340B hospitals, and non-340B hospitals, he explained.
In addition to Udenyca, Coherus is currently advancing 2 additional late-stage biosimilar programs: an adalimumab biosimilar referencing Humira and an etanercept biosimilar referencing Enbrel. It is also developing ophthalmology biosimilars, including ranibizumab, referencing Lucentis, and aflibercept, referencing Eylea. It is also developing CHS-131, a novel small-molecule agent that is intended to treat both nonalcoholic steatohepatitis and multiple sclerosis.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
